Spondyloarthritis

      smartphone
      Harnessing AI in axSpA: The Promise of Digital Therapeutics with Axia
      4 months 1 week ago
      The management of axial spondyloarthritis (axSpA) continues to evolve with the integration of artificial intelligence and digital health technologies. At #EULAR2025, the Bechterew-App Trial (LB0002) presented important new data on Axia, a novel AI-powered digital therapeutic developed for axSpA.
      MRI Lesions in Early axSpA vs Non-axSpA
      4 months 1 week ago
      Efficacy and Safety of Xeligekimab in AS

      Dr. Adela Castro reports on abstract OP0102 at the EULAR 2025 meeting in Barce

      Dr. John Cush RheumNow

      4 months 1 week ago
      Efficacy and Safety of Xeligekimab in AS Dr. Adela Castro reports on abstract OP0102 at the EULAR 2025 meeting in Barcelona, Spain https://t.co/xpzeV0oZOr https://t.co/mEYnAFsYQI
      ⌛️ Diagnostic delay in #SpA: Better with time?

      🔹️Data from the @Official_ASAS
      Study
      🔹️4339 patients
      🔹?

      Nelly ZIADE 🍀 Nellziade

      4 months 1 week ago
      ⌛️ Diagnostic delay in #SpA: Better with time? 🔹️Data from the @Official_ASAS Study 🔹️4339 patients 🔹️Delay decreased over time 🔹️Same trends across world regions & across Human Development Index categories POS0908 #EULAR2025 @RheumNow https://t.co/Y9gxQDV9KJ
      Impact of TNFi on efficacy of Vunakizumab in AS.
      -Post hoc analysis of Vunakizumab
      (humanized monoclonal IgG1/k antibod

      Adela Castro AdelaCastro222

      4 months 1 week ago
      Impact of TNFi on efficacy of Vunakizumab in AS. -Post hoc analysis of Vunakizumab (humanized monoclonal IgG1/k antibody targeting IL-17A) trial on AS pts. -440 total pts, 163 had prior TNFi exposure - At week 16, no significant differences in ASAS20 b/w TNFi exposed pts https://t.co/O9PFOuLa5l
      Sacroiliac joint involvement in #Psoriatic_arthritis

      🔹️681 patients
      🔹️Age 45
      🔹️31% MRI-positive sacroili

      Nelly ZIADE 🍀 Nellziade

      4 months 1 week ago
      Sacroiliac joint involvement in #Psoriatic_arthritis 🔹️681 patients 🔹️Age 45 🔹️31% MRI-positive sacroiliitis 🔹️29% radiographic sacroiliitis 🔹️AxPsS associated with: peripheral arthritis, dactylitis, nail psoriasis POS0297 #EULAR2025 @RheumNow https://t.co/gKANc6mNZB
      Data from COAST-V study (post hoc)

      🔹️Ixekizumab in #axSpA
      🔹️Efficacy stratified by CRP level
      🔹️Better tr

      Nelly ZIADE 🍀 Nellziade

      4 months 1 week ago
      Data from COAST-V study (post hoc) 🔹️Ixekizumab in #axSpA 🔹️Efficacy stratified by CRP level 🔹️Better treatment response in the elevated compared to the normal CRP group OP0699 #EULAR2025 @RheumNow https://t.co/1mVoly3Gws
      Is there an association btwn ⬆️ CRP & cardiovascular dysfunction in #axSpA?

      🔹️245 pts
      🔹️CRP recorded

      Nelly ZIADE 🍀 Nellziade

      4 months 1 week ago
      Is there an association btwn ⬆️ CRP & cardiovascular dysfunction in #axSpA? 🔹️245 pts 🔹️CRP recorded for past 5y 🔹️sustained high CRP in 40% 🔹️associated with ⬆️ cardiovascular risk factors, ⬇️endothelial function & subclin atheroslerosis POS0714 #EULAR2025 @RheumNow https://t.co/jAlj3sr95H
      RCT of a digital intervention in RMDs? It was long awaited, and all the lights are green🟢!

      German national Bechterew

      Aurelie Najm AurelieRheumo

      4 months 1 week ago
      RCT of a digital intervention in RMDs? It was long awaited, and all the lights are green🟢! German national Bechterew-App RCT of App based intervention AXIA, control group was standard of care 200pts 12wks ASAS20 response 51% vs. 9% ASAS40 response rate 23% vs. 3% BASDAI:
      67% of HCPs knew of EULAR’s CVD risk guidelines in RMDs—but few could apply them.
      ✅ Only 13% linked SLE control to

      Jiha Lee JihaRheum

      4 months 1 week ago
      67% of HCPs knew of EULAR’s CVD risk guidelines in RMDs—but few could apply them. ✅ Only 13% linked SLE control to CVD risk 🚫 0% picked correct BP/statin use in RA/AS/PsA Barriers? Time, knowledge, and local guideline gaps. POS0410-HPR @RheumNow #EULAR2025
      📱 Axia, a digital therapeutic for #axSpa, led to significant improvements in BASDAI, BASFI & ASQoL in a 12-week R

      Mrinalini Dey DrMiniDey

      4 months 1 week ago
      📱 Axia, a digital therapeutic for #axSpa, led to significant improvements in BASDAI, BASFI & ASQoL in a 12-week RCT. ASAS20: 51% vs 9%; ASAS40: 23% vs 3%. Promising app-based intervention comprising individualised exercise, pt education & disease Mx. @RheumNow #EULAR2025 #LB0002
      #EULAR2025 Abstr#LB0002 Crossover RCT of use of AXIA - a novel app-based intervention showed improvement in disease acti

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 months 1 week ago
      #EULAR2025 Abstr#LB0002 Crossover RCT of use of AXIA - a novel app-based intervention showed improvement in disease activity, functionality & quality of life in pople with Axial #SpA vs usual care. Available in Austria currently - awaiting rollout and in other languages @RheumNow https://t.co/nV4QifyikL
      Self-management of rheum disease is ripe for apps, gamification. How well does it work though?

      This app (Axia) in axSpA

      David Liew drdavidliew

      4 months 1 week ago
      Self-management of rheum disease is ripe for apps, gamification. How well does it work though? This app (Axia) in axSpA was basically as good as a biologic. Maybe you downplay non-pharm management, prob because we don’t do it well. This changes that #EULAR2025 LB0002 @RheumNow https://t.co/sfhEJFsF89
      Suppression of inflammation fire 🔥 in #axSpA
      may prevent subclinical atherosclerosis progression ❤️

      🔺️90

      Nelly ZIADE 🍀 Nellziade

      4 months 1 week ago
      Suppression of inflammation fire 🔥 in #axSpA may prevent subclinical atherosclerosis progression ❤️ 🔺️90 patients 🔺️74% achieved LDA at 12 mo 🔺️Carotid plaque progression was higher in non-LDA group POS1311 #EULAR2015 @RheumNow
      RA is worst with temperature rising/ climate change.
      However SpA has the opposite effect!
      Climate change session at #EU

      Bella Mehta bella_mehta

      4 months 1 week ago
      RA is worst with temperature rising/ climate change. However SpA has the opposite effect! Climate change session at #EULAR2025 @RheumNow https://t.co/eKVXnfdEzD

      Catch up on Conference Podcasts

      ×